Processa pharmaceuticals announces next generation capecitabine (combination of pcs6422 and capecitabine) inhibits dpd in phase 1b interim analysis

Hanover, md, nov. 04, 2021 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa), (“processa” or the “company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announced today that the company's next generation capecitabine dosage regimen (a combination of pcs6422 administered with capecitabine) successfully inhibited dihydropyrimidine dehydrogenase (dpd), altering the metabolism of 5-fluoruracil (5-fu) at least during the first 24-48 hours after pcs6422 administration but not throughout the 7 days of capecitabine dosing. if next generation capecitabine inhibits the metabolism of 5-fu throughout capecitabine dosing, the combination product could be a more potent and safer cancer treatment than current chemotherapy drugs including fda approved capecitabine, opening a multi-billion-dollar cancer chemotherapy market across multiple types of cancer.
PCSA Ratings Summary
PCSA Quant Ranking